Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma

por Rosner, Samuel, Agrawal, Yuri, Sun, Daniel Q, Aygun, Nafi, Schollenberger, Megan D, Lipson, Evan, Naidoo, Jarushka
Publicado 2020

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade

por Lipson, Evan J., Lilo, Mohammed T., Ogurtsova, Aleksandra, Esandrio, Jessica, Xu, Haiying, Brothers, Patricia, Schollenberger, Megan, Sharfman, William H., Taube, Janis M.
Publicado 2017

Utility of Serial Donor-derived Cell-free DNA Measurements for Detecting Allograft Rejection in a Kidney Transplant Recipient After PD-1 Checkpoint Inhibitor Administration

por Lakhani, Laila, Alasfar, Sami, Bhalla, Anshul, Aala, Amtul, Rosenberg, Avi, Ostrander, Darin, Schollenberger, Megan D., Brennan, Daniel C., Lipson, Evan J.
Publicado 2021

Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series

por LoPiccolo, Jaclyn, Schollenberger, Megan D., Dakhil, Sumia, Rosner, Samuel, Ali, Osama, Sharfman, William H., Silk, Ann W., Bhatia, Shailender, Lipson, Evan J.
Publicado 2019

Anti-RA33 antibodies are present in a subset of patients with immune checkpoint inhibitor-induced inflammatory arthritis

por Cappelli, Laura C, Bingham, Clifton O, Forde, Patrick M, Anagnostou, Valsamo, Brahmer, Julie, Lipson, Evan J, Mammen, Jennifer, Schollenberger, Megan, Shah, Ami A, Darrah, Erika
Publicado 2022

From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real‐world setting

por Rowe, Steven P., Luber, Brandon, Makell, Monique, Brothers, Patricia, Santmyer, JoAnn, Schollenberger, Megan D., Quinn, Hannah, Edelstein, Daniel L., Jones, Frederick S., Bleich, Karen B., Sharfman, William H., Lipson, Evan J.
Publicado 2018